Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ASTRAZENECA PHARMA   ACTAVIS
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-23
ACTAVIS
Dec-18
ASTRAZENECA PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs3,62016,126-   
Low Rs2,43810,818-   
Sales per share (Unadj.) Rs401.23,955.8-  
Earnings per share (Unadj.) Rs39.7-1,274.2-  
Cash flow per share (Unadj.) Rs46.2416.9-  
Dividends per share (Unadj.) Rs16.000-  
Avg Dividend yield %0.50-  
Book value per share (Unadj.) Rs234.416,315.7-  
Shares outstanding (eoy) m25.00332.60-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x7.53.4 221.7%   
Avg P/E ratio x76.3-10.6 -721.3%  
P/CF ratio (eoy) x65.532.3 202.8%  
Price / Book Value ratio x12.90.8 1,564.6%  
Dividend payout %40.30-   
Avg Mkt Cap Rs m75,7184,480,758 1.7%   
No. of employees `000NA16.9 0.0%   
Total wages/salary Rs m2,5910-   
Avg. sales/employee Rs Th077,851.4-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0-25,076.0-  
INCOME DATA
Net Sales Rs m10,0301,315,689 0.8%  
Other income Rs m26125,160 1.0%   
Total revenues Rs m10,2911,340,849 0.8%   
Gross profit Rs m1,24934,478 3.6%  
Depreciation Rs m163562,428 0.0%   
Interest Rs m675,923 0.0%   
Profit before tax Rs m1,341-578,713 -0.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0147,595 0.0%   
Tax Rs m348-7,334 -4.7%   
Profit after tax Rs m993-423,784 -0.2%  
Gross profit margin %12.52.6 475.2%  
Effective tax rate %26.01.3 2,048.3%   
Net profit margin %9.9-32.2 -30.7%  
BALANCE SHEET DATA
Current assets Rs m9,359539,627 1.7%   
Current liabilities Rs m4,844477,372 1.0%   
Net working cap to sales %45.04.7 951.5%  
Current ratio x1.91.1 170.9%  
Inventory Days Days4920 252.6%  
Debtors Days Days3966 59.0%  
Net fixed assets Rs m2,061148,929 1.4%   
Share capital Rs m500-   
"Free" reserves Rs m5,8110-   
Net worth Rs m5,8615,426,601 0.1%   
Long term debt Rs m01,910,903 0.0%   
Total assets Rs m11,4218,483,012 0.1%  
Interest coverage x213.9-6.6 -3,229.3%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.90.2 566.2%   
Return on assets %8.7-4.1 -213.4%  
Return on equity %16.9-7.8 -216.9%  
Return on capital %23.0-4.8 -474.9%  
Exports to sales %00-   
Imports to sales %37.40-   
Net fx Rs m-3,1350-   
CASH FLOW
From Operations Rs m583470,046 0.1%  
From Investments Rs m181258,229 0.1%  
From Financial Activity Rs m-245-806,740 0.0%  
Net Cashflow Rs m519-78,073 -0.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 83.34 Rs / USD

Compare ASTRAZENECA PHARMA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare ASTRAZENECA PHARMA With: GLENMARK LIFE SCIENCES  BAL PHARMA  ZOTA HEALTH CARE  HEMO ORGANIC  KIMIA BIOSCIENCES  



Today's Market

Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising(Closing)

After opening the day on positive note, Indian share markets gained the momentum as the session progressed and ended on firm footing.